All In Biotech

Drug Trial Radar · NCT00334958

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Last checked: Nov 19, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

356

Actual

Start

Feb 13, 2006

Primary completion

May 20, 2009

Study completion May 20, 2009

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jun 8, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).

Conditions

  • Epilepsy

Interventions

  • PlaceboDrug

    For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.

  • RufinamideDrug

    For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline PhaseTime frame: Baseline, Days 13 to 96

Locations

77 sites in 1 country. Site status is shown where the registry gives one.

  • University of South Alabama Medical Center

    Mobile, Alabama

  • Neurology Clinic PC

    Northport, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Mayo Clinic Epilepsy and Neurology

    Phoenix, Arizona

  • University of Arizona, Dept. of Neurology

    Tucson, Arizona

  • Clinical Trials, Inc

    Little Rock, Arkansas

  • Neuro-Pain Medical Center, Inc.

    Fresno, California

  • Neurology Center

    Oceanside, California

  • California Pacific Epilepsy

    San Francisco, California

  • Georgetown University Hospital, Dept. of Neurology

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Bradenton Research Center

    Bradenton, Florida

  • University of Florida, Dept. of Neurology

    Gainesville, Florida

  • University of Florida, The Neuroscience Institute at Shands

    Jacksonville, Florida

  • Pediatric Neurologists of Palm Beach

    Loxahatchee Groves, Florida

  • Nemours Children's Clinic

    Orlando, Florida

  • Pediatric Neurology - PA

    Orlando, Florida

  • Bay Medical Center

    Panama City, Florida

  • University of Southern Florida, Dept. of Neurology

    Tampa, Florida

  • Child Neurology Associates, PC

    Atlanta, Georgia

  • Medical College of Georgia, Dept. of Neurology

    Augusta, Georgia

  • Medical Associates of North Georgia

    Canton, Georgia

  • The Queen's Medical Center

    Honolulu, Hawaii

  • Children's Memorial Hospital, Northwest University

    Chicago, Illinois

  • Advocate Hope Children's Hospital

    Oak Lawn, Illinois

  • Advocate Lutheran General Children's Hospital

    Park Ridge, Illinois

  • Southern Illinois University Neurology and Pharmacology

    Springfield, Illinois

  • Mcfarland Clinic

    Ames, Iowa

  • Via Christi Comprehensive Epilepsy Center

    Wichita, Kansas

  • University of Kentucky, Dept. of Neurology

    Lexington, Kentucky

  • John Hopkins Hospital, Dept. of Neurology

    Baltimore, Maryland

  • Children's Hospital Boston

    Boston, Massachusetts

  • Boston University Medical Center, Dept. of Neurology

    Boston, Massachusetts

  • University of Massachusetts, Neurology Associates

    Hopedale, Massachusetts

  • University of Minnesota, Dept. of Neurology

    Minneapolis, Minnesota

  • Minnesota Epilepsy Group, PC

    Saint Paul, Minnesota

  • Ronald Schwartz, M.D.

    Hattiesburg, Mississippi

  • Hattiesburg Clinic

    Hattiesburg, Mississippi

  • The Comprehensive Epilepsy Care Center for Children and Adults

    Chesterfield, Missouri

  • Saint John's Medical Research

    Springfield, Missouri

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.